218 related articles for article (PubMed ID: 22761669)
1. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.
Yin JY; Huang Q; Zhao YC; Zhou HH; Liu ZQ
PLoS One; 2012; 7(6):e38150. PubMed ID: 22761669
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
Tan LM; Qiu CF; Zhu T; Jin YX; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jul; 7(1):5593. PubMed ID: 28717179
[TBL] [Abstract][Full Text] [Related]
3. The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Jul; 35(7):6791-9. PubMed ID: 24729086
[TBL] [Abstract][Full Text] [Related]
4. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.
Wei HB; Lu XS; Shang LH; Xu G; Hu J; Che DH; Liu F; Wu Y; Zhang GM; Yu Y
Arch Med Res; 2011 Jul; 42(5):412-20. PubMed ID: 21827803
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H; Tan SC
Mol Biol Rep; 2024 Jan; 51(1):102. PubMed ID: 38217759
[TBL] [Abstract][Full Text] [Related]
7. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
[TBL] [Abstract][Full Text] [Related]
8. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
9. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
10. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Chen J; Wang Z; Zou T; Cui J; Yin J; Zheng W; Jiang W; Zhou H; Liu Z
Oncotarget; 2016 Aug; 7(34):55741-55756. PubMed ID: 27248474
[TBL] [Abstract][Full Text] [Related]
12. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Zou HZ; Zhao YQ
Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer: A meta-analysis.
Huang Z; Xiong G
Int J Biol Markers; 2022 Jun; 37(2):170-177. PubMed ID: 35404148
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
16. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
17. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
Galvani E; Toffalorio F; Peters GJ; De Pas T; Giovannetti E
Curr Pharm Des; 2014; 20(24):3863-74. PubMed ID: 24138720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
